-
Use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes in stable patients with a history of myocardial infarction (MI). These results do not support the routine use of chelation therapy for treatment of patients who have had a prior MI.
-
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
Among deployed U.S. service members who died of combat or unintentional injuries and received autopsies, the prevalence of atherosclerosis varied by age and cardiovascular risk factors.
-
Adults with private health care insurance in the United States have suboptimal testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV). Clearly, increased awareness is needed regarding HBV and HCV infections, epidemiology, risk, and screening.
-
The authors concluded that in patients with AF, decreasing GFR was associated with a higher risk of cardiovascular events and bleeding. Apixaban as compared to warfarin reduced these risks regardless of renal function, with the greatest benefit seen in reducing major bleeding in those with impaired renal function.
-
A selective estrogen receptor modulator (SERM), also known as an estrogen agonist/antagonist, has been approved by the FDA for the treatment of dyspareunia (painful intercourse) in postmenopausal women. Ospemifene is manufactured by Penn Pharmaceuticals Services Ltd. and marketed by Shionogi Inc. as Osphena.
-
-
The injection of a dextrose solution in and around the knee (prolotherapy) is an alternative treatment for the pain of knee osteoarthritis. A randomized, controlled trial shows that prolotherapy is effective for long-term control of knee pain and improvement in knee function.